JUL 0 8 2005 U

PTO/SB/30 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

KC A

work Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/965,807
Filing Date	October 10, 2001
Examiner Name	Suzanne Marie Mayer
First Named Inventor	Reuben Matalon
Group Art Unit	1653
Attorney Docket Number	SHUTT-1-C1

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114		
a. Previously submitted		
i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on		
(Any unentered amendment(s) referred to above will be entered). ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on		
iii. Other		
b. Enclosed		
i. ⊠ Amendment/Reply ii □ Affidavit(s)/Declaration(s)		
iii.		
iv. Other		
2. Miscellaneous		
Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period ofmonths. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)		
b. Other		
3. Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.		
a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to		
Deposit Account No. <u>13-3402</u>		
i. XRCE fee required under 37 C.F.R. § 1.17(e)		
ii.		
b. Check in the amount of \$ 395.00 enclosed (small entity)		
c. Payment by credit card (Form PTO-2038 enclosed)		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED		
Name (Print /Type) Richard M. Lebovitz	Registration No. (Attorney/Agent) 37,067	
Signature	Date July 8, 2005	
CERTIFICATE OF MAILING OR TRANSMISSION		
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on:		
Name (Print /Type)		
Signature	Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Commissioner for Patents, Box RCE, Washington, DC 20231.

07/11/2005 SZEWDIE1 00000079 09965807

01 FC:2801

395.00 OP



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Reuben Matalon

Serial No.: 09/965,807

Group Art Unit: 1653

Filed: October 1, 2001

Examiner: Suzanne Marie Mayer

For: APARTOACYLASE GENE, PROTEIN, AND METHODS OF SCREENING FOR

MUTATIONS ASSOCIATED WITH CANAVAN DISEASE

REPLY FILED WITH REQUEST FOR CONTINUED EXAMINATION

Mail Stop: RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In connection with the Request for Continued Examination filed herewith, please amend the application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 8 of this paper.